Sumitomo Pharma (4506) Q4 2025 earnings summary

Executive summary

• Achieved a significant turnaround in FY2024, returning to profitability with net profit of 23.6 billion JPY after a prior year loss, driven by strong U.S./North America sales of ORGOVYX, GEMTESA, and MYFEMBREE, as well as structural reforms and cost reductions.

• Revenue reached 398.8 billion JPY, up 26.8% year-over-year, mainly from North America and key product growth.

• Major restructuring included spinning off regenerative medicine, transferring Asian operations to a joint venture, and workforce downsizing.

• Launched "Reboot 2027" to rebuild value creation, focusing on innovation in oncology, regenerative medicine/cell therapy, and CNS pipeline expansion.

• No dividends declared for FY2024 or forecasted for FY2025, prioritizing financial position improvement.

Financial highlights

• FY2024 revenue: 398.8 billion JPY (+26.8% YoY); core operating profit: 43.2 billion JPY (vs. -133.0 billion JPY prior year); net profit: 23.6 billion JPY (vs. -314.9 billion JPY prior year).

• SG&A expenses dropped by 68.7 billion JPY and R&D expenses by 42.4 billion JPY year-over-year.

• Operating cash flow turned positive at 16.5 billion JPY, up from negative 241.9 billion JPY in FY2023.

• Basic EPS: 59.49 JPY (vs. -792.79 JPY); equity ratio: 22.8% (up from 17.2%).

• Financial costs included an 11.2 billion JPY loss from foreign exchange and interest.

Outlook and guidance

• FY2025 revenue forecast: 355.0 billion JPY (-11.0% YoY), mainly due to Asia business transfer, FX impact, and loss of exclusivity for Equa/EquMet.

• Core operating profit forecast: 56.0 billion JPY (+29.8% YoY); net profit forecast: 40.0 billion JPY (+69.2% YoY).

• No dividends planned for FY2025 as financial recovery remains a priority.

• Focus remains on growth of ORGOVYX, MYFEMBREE, and GEMTESA, with strategic target of 250 billion JPY sales by FY2027.

• Long-term target: core operating profit to remain above 25 billion JPY after FY2027.